BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vallianou N, Kounatidis D, Christodoulatos GS, Panagopoulos F, Karampela I, Dalamaga M. Mycobiome and Cancer: What Is the Evidence? Cancers (Basel) 2021;13:3149. [PMID: 34202433 DOI: 10.3390/cancers13133149] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Yuan M, Xu Y, Guo Z. Association of oral microbiome and pancreatic cancer: a systematic review and meta-analysis. Therap Adv Gastroenterol 2022;15:17562848221123980. [PMID: 36171810 DOI: 10.1177/17562848221123980] [Reference Citation Analysis]
2 Zhou X, Kandalai S, Hossain F, Zheng Q. Tumor microbiome metabolism: A game changer in cancer development and therapy. Front Oncol 2022;12:933407. [DOI: 10.3389/fonc.2022.933407] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li Z, Liu Y, Zhang L. Role of the microbiome in oral cancer occurrence, progression and therapy. Microb Pathog 2022;169:105638. [PMID: 35718272 DOI: 10.1016/j.micpath.2022.105638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Gamal A, Elshaer M, Alabdely M, Kadry A, McCormick TS, Ghannoum M. The Mycobiome: Cancer Pathogenesis, Diagnosis, and Therapy. Cancers (Basel) 2022;14:2875. [PMID: 35740541 DOI: 10.3390/cancers14122875] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Fotis D, Liu J, Dalamaga M. Could gut mycobiome play a role in NAFLD pathogenesis? Insights and therapeutic perspectives. Metabolism Open 2022;14:100178. [DOI: 10.1016/j.metop.2022.100178] [Reference Citation Analysis]
6 Sultan AS, Theofilou VI, Alfaifi A, Montelongo-jauregui D, Jabra-rizk M. Is Candida albicans an opportunistic oncogenic pathogen? PLoS Pathog 2022;18:e1010413. [DOI: 10.1371/journal.ppat.1010413] [Reference Citation Analysis]
7 Dalamaga M, Zheng L, Liu J. Gut mycobiome as a promising preventive and therapeutic target for metabolic disorders. Metabolism Open 2022;13:100168. [DOI: 10.1016/j.metop.2022.100168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ibragimova S, Ramachandran R, Ali FR, Lipovich L, Ho SB. Dietary Patterns and Associated Microbiome Changes that Promote Oncogenesis. Front Cell Dev Biol 2021;9:725821. [PMID: 34869313 DOI: 10.3389/fcell.2021.725821] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
9 DiMaio D, Emu B, Goodman AL, Mothes W, Justice A. Cancer Microbiology. J Natl Cancer Inst 2021:djab212. [PMID: 34850062 DOI: 10.1093/jnci/djab212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Shahid RK, Ahmed S, Le D, Yadav S. Diabetes and Cancer: Risk, Challenges, Management and Outcomes. Cancers (Basel) 2021;13:5735. [PMID: 34830886 DOI: 10.3390/cancers13225735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
11 Schizas D, Koumpoura A, Galari M, Economopoulou P, Vailas M, Sotiropoulou M, Dimitroulis D, Maroulis I, Felekouras E. A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice. Per Med 2021;18:613-27. [PMID: 34676789 DOI: 10.2217/pme-2021-0031] [Reference Citation Analysis]
12 Silva M, Brunner V, Tschurtschenthaler M. Microbiota and Colorectal Cancer: From Gut to Bedside. Front Pharmacol 2021;12:760280. [PMID: 34658896 DOI: 10.3389/fphar.2021.760280] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]